Bausch Health Companies (BHC) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bausch Health Companies (BHC) has outperformed Disc Medicine (IRON) over the past year, losing 4.7% versus a loss of 13.5%. Over five years, IRON leads with a -45.5% price change compared with -78.8% for BHC. Disc Medicine is the larger company by market cap ($2.33 billion vs $2.26 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | IRON |
|---|---|---|
| Share price | $6.04 | $60.77 |
| Market cap | $2.26B | $2.33B |
| 1-day change | -1.79% | -0.67% |
| YTD return | -13.09% | -23.47% |
| 1-year return | -4.73% | -13.53% |
| 5-year return | -78.80% | -45.55% |
| Forward P/E | 1.44 | — |
| EPS (TTM) | $-2.95 | $-6.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $99.50 |
| 52-week low | $4.33 | $40.00 |
| Distance from 52-week high | -24.50% | -38.92% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +24.17% | +69.77% |
| Average volume | 3.24M | 462.73K |
| Shares outstanding | 373.99M | 38.39M |
| Employees | 20,300 | 165 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
BHC vs IRON FAQ
Which is bigger, Bausch Health Companies or Disc Medicine?
Disc Medicine (IRON) is larger, with a market capitalization of $2.33B compared with $2.26B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or IRON?
BHC returned -4.73% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Disc Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.